Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00387686




Registration number
NCT00387686
Ethics application status
Date submitted
11/10/2006
Date registered
13/10/2006
Date last updated
28/02/2013

Titles & IDs
Public title
A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures
Scientific title
A Phase 2/3, Multicenter, Double-Blind, Randomized, Controlled Study Of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) In Closed Diaphyseal Tibial Fracture
Secondary ID [1] 0 0
3100N7-210
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Fractures 0 0
Condition category
Condition code
Injuries and Accidents 0 0 0 0
Fractures
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - rhBMP-2/CPM
Treatment: Drugs - rhBMP-2/CPM
Treatment: Drugs - rhBMP-2/CPM
Treatment: Drugs - rhBMP-2/CPM

Experimental: A - 1.0 mg/mL rhBMP-2/CPM + surgical fixation

Experimental: B - 2.0 mg/mL rhBMP-2/CPM + surgical fixation

Active Comparator: C - Buffer/CPM + surgical fixation Intervention

Other: D - Standard of Care: Surgical fixation intervention


Treatment: Drugs: rhBMP-2/CPM


Treatment: Drugs: rhBMP-2/CPM


Treatment: Drugs: rhBMP-2/CPM


Treatment: Drugs: rhBMP-2/CPM
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The primary objective of this study is to assess whether a single dose of rhBMP-2/CPM administered in combination with the SOC accelerates fracture union and return to normal function as indicated on radiographs and functional evaluations.
Timepoint [1] 0 0
efficacy will be demonstrated if there is a greater than or equal to 4 week reduction in time to fra
Secondary outcome [1] 0 0
Demonstrate safety of rhBMP-2/CPM administration; demonstrate earlier return to function; assess feasibility of rhBMP-2CPM administration. Subject enrollment 12 months
Timepoint [1] 0 0
12 months

Eligibility
Key inclusion criteria
- Skeletally mature, male and female subjects who are at least 18 years old.

- Closed diaphyseal tibial fracture.

- Closed reduction and definitive internal fixation by means of a reamed, locked
intramedullary nail within 72 hours after injury.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Concurrent fractures of the ipsilateral or contralateral lower extremity other than
the ipsilateral fibula, that would impede performance on the functional assessment of
weight bearing.

- Planned procedure(s) to stimulate fracture healing after intramedullary nailing.

- Neurovascular impairment of the fractured limb, deep vein thrombosis, or (impending)
compartment syndrome.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2/Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/03/2010
Sample size
Target
Accrual to date
Final
367
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA
Recruitment hospital [1] 0 0
Pfizer Investigational Site - Liverpool
Recruitment hospital [2] 0 0
Pfizer Investigational Site - New Lambton
Recruitment hospital [3] 0 0
Pfizer Investigational Site - Herston
Recruitment hospital [4] 0 0
Pfizer Investigational Site - Adelaide
Recruitment postcode(s) [1] 0 0
2170 - Liverpool
Recruitment postcode(s) [2] 0 0
2305 - New Lambton
Recruitment postcode(s) [3] 0 0
4029 - Herston
Recruitment postcode(s) [4] 0 0
5000 - Adelaide
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Indiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
New Hampshire
Country [9] 0 0
United States of America
State/province [9] 0 0
New Jersey
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Tennessee
Country [13] 0 0
Argentina
State/province [13] 0 0
Buenos Aires
Country [14] 0 0
Brazil
State/province [14] 0 0
Sao Paolo
Country [15] 0 0
Brazil
State/province [15] 0 0
Sao Paulo
Country [16] 0 0
Canada
State/province [16] 0 0
Ontario
Country [17] 0 0
Canada
State/province [17] 0 0
Quebec
Country [18] 0 0
Finland
State/province [18] 0 0
Oulu
Country [19] 0 0
Finland
State/province [19] 0 0
Turku
Country [20] 0 0
France
State/province [20] 0 0
Angers
Country [21] 0 0
France
State/province [21] 0 0
Créteil
Country [22] 0 0
France
State/province [22] 0 0
Marseille
Country [23] 0 0
France
State/province [23] 0 0
Toulouse
Country [24] 0 0
Germany
State/province [24] 0 0
Berlin
Country [25] 0 0
Germany
State/province [25] 0 0
Mainz
Country [26] 0 0
Germany
State/province [26] 0 0
Muenster
Country [27] 0 0
India
State/province [27] 0 0
Andhra Pradesh
Country [28] 0 0
India
State/province [28] 0 0
Gujarat
Country [29] 0 0
India
State/province [29] 0 0
Karnataka
Country [30] 0 0
India
State/province [30] 0 0
Maharashtra
Country [31] 0 0
Latvia
State/province [31] 0 0
Riga
Country [32] 0 0
Mexico
State/province [32] 0 0
Del Miguel, Hidalgo
Country [33] 0 0
Mexico
State/province [33] 0 0
Guadalajara, Jal.
Country [34] 0 0
Mexico
State/province [34] 0 0
Mexico D.F.
Country [35] 0 0
Mexico
State/province [35] 0 0
Chihuahua
Country [36] 0 0
Mexico
State/province [36] 0 0
Guadalajara, Jal
Country [37] 0 0
Poland
State/province [37] 0 0
Bielsk Podlaski
Country [38] 0 0
Poland
State/province [38] 0 0
Krakow
Country [39] 0 0
Romania
State/province [39] 0 0
Cluj
Country [40] 0 0
Romania
State/province [40] 0 0
Bucharest
Country [41] 0 0
Romania
State/province [41] 0 0
Bucuresti
Country [42] 0 0
Romania
State/province [42] 0 0
Iasi
Country [43] 0 0
Serbia
State/province [43] 0 0
Belgrade
Country [44] 0 0
Serbia
State/province [44] 0 0
Nis
Country [45] 0 0
Slovenia
State/province [45] 0 0
Ljubljana
Country [46] 0 0
Spain
State/province [46] 0 0
Madrid
Country [47] 0 0
Spain
State/province [47] 0 0
Alcala
Country [48] 0 0
Sweden
State/province [48] 0 0
Uppsala
Country [49] 0 0
United Kingdom
State/province [49] 0 0
Coventry
Country [50] 0 0
United Kingdom
State/province [50] 0 0
Norwich

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Wyeth is now a wholly owned subsidiary of Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of this study is to assess whether a single dose of rhBMP-2/CPM
administered at the fracture site via percutaneous injection, in combination with standard of
care, accelerates fracture union and return to normal function in subjects who have a closed
diaphyseal tibial fracture when compared to standard of care alone.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00387686
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00387686